U.S. Capital Wealth Advisors LLC Acquires 1,385 Shares of Amgen Inc. $AMGN

Key Points

• U.S. Capital Wealth Advisors LLC acquired an additional 1,385 shares of Amgen Inc., increasing its holdings by 7.8% to a total of 19,156 shares, valued at approximately $5.35 million.
• Several institutional investors, including KPP Advisory Services LLC and Trinity Legacy Partners LLC, also significantly increased their stakes in Amgen during the first quarter of the year.
• Amgen reported a strong quarterly performance, with earnings per share of $6.02, exceeding analyst expectations, and projected a full year EPS range of 20.200-21.300 for fiscal year 2025.

U.S. Capital Wealth Advisors LLC increased its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 7.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,156 shares of the medical research company's stock after purchasing an additional 1,385 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Amgen were worth $5,349,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. KPP Advisory Services LLC increased its stake in Amgen by 87.1% in the 1st quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company's stock worth $1,817,000 after purchasing an additional 2,716 shares during the period. Advisor Resource Council bought a new position in shares of Amgen in the first quarter worth approximately $1,331,000. Trinity Legacy Partners LLC increased its stake in shares of Amgen by 3.9% in the first quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company's stock worth $5,026,000 after buying an additional 612 shares during the period. DLK Investment Management LLC raised its holdings in Amgen by 7.3% during the 1st quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company's stock valued at $6,384,000 after buying an additional 1,387 shares during the last quarter. Finally, Founders Financial Alliance LLC boosted its position in Amgen by 2.7% during the 1st quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company's stock valued at $491,000 after buying an additional 42 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. Piper Sandler raised their price target on shares of Amgen from $328.00 to $342.00 and gave the stock an "overweight" rating in a report on Monday, August 25th. William Blair restated an "outperform" rating on shares of Amgen in a report on Tuesday, June 24th. UBS Group lowered their price target on Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a research report on Wednesday, August 6th. Bank of America lifted their price objective on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research report on Wednesday, July 23rd. Finally, Morgan Stanley upped their target price on Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $304.43.

Amgen Price Performance

AMGN opened at $286.00 on Tuesday. The firm has a market cap of $153.97 billion, a PE ratio of 23.39, a P/E/G ratio of 2.48 and a beta of 0.49. The stock has a 50-day moving average price of $290.35 and a 200-day moving average price of $290.02. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $339.17. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts' consensus estimates of $5.28 by $0.74. The business had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen's revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a $2.38 dividend. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.3%. Amgen's dividend payout ratio is 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company's stock, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.69% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.